An Open Label, Pilot Study of Dose-Dense Adriamycin [doxorubicin] Plus Cyclophosphamide (AC) Followed by ABI-007 [Abraxane, paclitaxel] as Adjuvant Therapy for Patients With Breast Cancer.

Trial Profile

An Open Label, Pilot Study of Dose-Dense Adriamycin [doxorubicin] Plus Cyclophosphamide (AC) Followed by ABI-007 [Abraxane, paclitaxel] as Adjuvant Therapy for Patients With Breast Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Jul 2007

At a glance

  • Drugs Cyclophosphamide; Doxorubicin; Paclitaxel
  • Indications Early breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Jul 2007 Status changed from in progress to completed.
    • 24 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top